Ultragenyx Pharmaceutical Inc. share price logo

Ultragenyx Pharmaceutical Inc. Share Price

NASDAQ: RARE

Mid Cap

$22.84

+0.23

(+1.00%)

Live

as on

Ultragenyx Pharmaceutical Inc. Stock Performance

as on March 11, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $22.38
    $23.19
    downward going graph

    2.01%

    Downside

    1.53%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $18.41
    $42.37
    downward going graph

    19.40%

    Downside

    85.51%

    Upside

    downward going graph

Ultragenyx Pharmaceutical Inc. share price movements today

Previous Close
$22.61
Open
$22.74
Volume
683.9K
Day's Low - High
$22.38 - $23.19
52 Week Low - High
$18.41 - $42.37

Ultragenyx Pharmaceutical Inc. Historical Returns

1 Month Return
-6.57 %
3 Month Return
-37.19 %
1 Year Return
-39.71 %
3 Year Return
-41.67 %
5 Year Return
-81.15 %

Ultragenyx Pharmaceutical Inc. Stock Fundamentals & Key Indicators

Check Ultragenyx Pharmaceutical Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-4.382

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-8.97

Industry PE ratio

7.871681415929204

PEG Ratio

-0.24

EBITDA

-500.0M

Revenue (TTM)

673.0M

Profit Margin

-85.44%

Return On Equity TTM

-608.47%

Ultragenyx Pharmaceutical Inc. Stock Valuation

Track how Ultragenyx Pharmaceutical Inc. P/E has moved over time to understand its valuation trends.

Ultragenyx Pharmaceutical Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-43.63x)

March 31, 2021

Today (-8.97x)

March 10, 2026

Industry (7.87x)

March 10, 2026

Highest (-3.89x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -8.97x

Ultragenyx Pharmaceutical Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ultragenyx Pharmaceutical Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Ultragenyx Pharmaceutical Inc. image
Ultragenyx Pharmaceutical Inc.
BUY$2.1B-81.15%-8.97-85.44%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.5B140.27%137.038.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$116.0B115.07%29.8532.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$33.3BNA590.435.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.3B67.03%18.3131.41%

Stock Returns calculator for Ultragenyx Pharmaceutical Inc. Stock including INR - Dollar returns

The Ultragenyx Pharmaceutical Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ultragenyx Pharmaceutical Inc. investment value today

Current value as on today

₹66,099

Returns

₹33,901

(-33.9%)

Returns from Ultragenyx Pharmaceutical Inc. Stock

₹39,093 (-39.09%)

Dollar Returns*

₹5,192 (+5.19%)

Analyst Recommendation on Ultragenyx Pharmaceutical Inc. Stock

Based on 27 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 27 analysts, 88.89% of analysts recommend a 'BUY' rating for Ultragenyx Pharmaceutical Inc.. Average target price of $56.55

Ultragenyx Pharmaceutical Inc. Share Price Target

Get share price movements and forecasts by analysts on Ultragenyx Pharmaceutical Inc..

What analysts predicted

59.61%UPSIDE

Target Price

$56.55

Current Price

$22.84

Analyzed by

27 Analysts

Target

$56.55

Ultragenyx Pharmaceutical Inc. target price $56.55, a slight upside of 59.61% compared to current price of $22.84. According to 27 analysts rating.

Ultragenyx Pharmaceutical Inc. Stock’s Investor Sentiment and Interest

Search interest for Ultragenyx Pharmaceutical Inc. Stock has decreased by -58% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-58% versus previous 30 day period

Ultragenyx Pharmaceutical Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
98
127
108
147
139
164
139
166
159
207
Gross Profit
87
115
91
125
118
147
110
143
131
178
Operating Income
-145
-122
-165
-116
-131
-122
-142
-107
-170
-114
EBITDA
-134
-101
-145
-105
-108
-108
-126
-91
-156
-105
Interest Expense
17
17
15
15
15
15
14
14
14
19
Depreciation
7
8
8
8
8
9
8
8
8
8
Income Before Tax
-158
-126
-170
-130
-133
-133
-149
-114
-179
-128
Income Tax Expense
0
-3
0
0
0
0
1
0
0
1
Net Income
-159
-123
-170
-131
-133
-133
-151
-114
-180
-129
Net Profit Margin
-162.82%
-96.70%
-156.83%
-89.51%
-95.71%
-80.90%
-108.46%
-69.04%
-112.81%
-62.32%

Ultragenyx Pharmaceutical Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
2
51
103
271
351
363
434
560
673
Gross Profit
0
2
50
94
264
335
335
389
483
564
Operating Income
-248
-328
-371
-424
-330
-381
-648
-569
-535
-535
EBITDA
-244
-323
-177
-389
-139
-410
-640
-516
-469
-500
Interest Expense
-
-
-
1
33
29
43
66
63
62
Depreciation
-
5
19
8
12
13
18
26
35
35
Income Before Tax
-245
-318
-197
-399
-185
-452
-701
-608
-567
-571
Income Tax Expense
0
-16
0
3
1
1
5
-1
1
4
Net Income
-245
-302
-197
-402
-186
-454
-707
-606
-569
-575
Net Profit Margin
-184867.67%
-11567.34%
-383.75%
-388.31%
-68.84%
-129.20%
-194.71%
-139.70%
-101.60%
-85.44%

Ultragenyx Pharmaceutical Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-123
-170
-131
-133
-133
-151
-114
-180
-129
Operating Cash Flow
-83
-190
-76
-66
-79
-166
-108
-91
-99
Investing Cash Flow
-107
94
60
-275
102
119
71
117
-72
Financing Cash Flow
330
0
384
11
3
0
83
0
394
Change in Cash
140
-97
367
-330
23
-44
49
26
221

Ultragenyx Pharmaceutical Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-302
-197
-402
-186
-454
-707
-606
-569
-575
Operating Cash Flow
-253
-290
-345
-132
-338
-380
-474
-414
-466
Investing Cash Flow
56
-33
-13
-179
-195
-291
168
-17
236
Financing Cash Flow
136
336
679
600
118
501
388
399
478
Change in Cash
-60
12
320
290
-416
-171
81
-35
253

Global Institutional Holdings in Ultragenyx Pharmaceutical Inc.

Funds
Holdings
BlackRock Inc
6.65%
Baker Bros Advisors LP
2.87%
Alkeon Capital Management, LLC
1.75%
Deutsche Bank AG
1.6%
Aberdeen Group PLC
1.52%
See all

Ultragenyx Pharmaceutical Inc. News & Key Events

  • img

    Today's Timeline - 29 December

    Mon, 08:45 PM

    -

    Ultragenyx shares hit 52-week low, down 43.96% after drug trials failed to meet primary endpoints.

Insights on Ultragenyx Pharmaceutical Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -180.41M → -129.0M (in $), with an average increase of 39.9% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 159.93M → 207.0M (in $), with an average increase of 22.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 77.2% return, outperforming this stock by 118.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 38.8% return, outperforming this stock by 78.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, RARE stock has moved down by -37.2%

About Ultragenyx Pharmaceutical Inc.

ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
OrganisationUltragenyx Pharmaceutical Inc.
Headquarters60 Leveroni Court, Novato, CA, United States, 94949
IndustryHealth Technology
CEODr. Emil D. Kakkis M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Ultragenyx Pharmaceutical Inc.

Name

Title

Dr. Emil D. Kakkis M.D., Ph.D.

Founder, President, CEO & Director

Mr. Erik Harris M.B.A.

Executive VP & Chief Commercial Officer

Mr. Theodore A. Huizenga

Senior VP, Corporate Controller & Principal Accounting Officer

Mr. Dennis Karl Huang

Chief Technical Operations Officer and Executive VP of Gene Therapy Operations

Mr. Ernie W. Meyer

Chief Human Resources Officer & Executive VP

Mr. Vimal Srivastava

Senior Vice President of Business Development & Alliance Management

Mr. Howard Horn

Executive VP of Corporate Strategy & CFO

Mr. John Richard Pinion II

Chief Quality Operations Officer & Executive VP of Translational Sciences

Dr. Eric Crombez M.D.

Chief Medical Officer & Executive VP

Ms. Karah Herdman Parschauer J.D.

Chief Legal Officer & Executive VP of Corporate Affairs

FAQs

What is Ultragenyx Pharmaceutical Inc. share price today?

Ultragenyx Pharmaceutical Inc. share price today is $22.84 as on . Ultragenyx Pharmaceutical Inc. share today touched a day high of $23.19 and a low of $22.38.

What is the 52 week high and 52 week low for Ultragenyx Pharmaceutical Inc. share?

Ultragenyx Pharmaceutical Inc. share touched a 52 week high of $42.37 on and a 52 week low of $18.41 on . Ultragenyx Pharmaceutical Inc. stock price today i.e. is trending at $22.84,which is 46.09% down from its 52 week high and 24.06% up from its 52 week low.

What is Ultragenyx Pharmaceutical Inc.'s market capitalisation today?

Ultragenyx Pharmaceutical Inc. market capitalisation is $0.00T as on .

How to invest in Ultragenyx Pharmaceutical Inc. Stock (RARE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ultragenyx Pharmaceutical Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ultragenyx Pharmaceutical Inc. Shares that will get you 0.0657 shares as per Ultragenyx Pharmaceutical Inc. share price of $22.84 per share as on March 11, 2026 at 1:29 am IST.

What is the minimum amount required to buy Ultragenyx Pharmaceutical Inc. Stock (RARE) from India?

Indian investors can start investing in Ultragenyx Pharmaceutical Inc. (RARE) shares with as little as ₹91.833 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹918.33 in Ultragenyx Pharmaceutical Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Ultragenyx Pharmaceutical Inc. share’s latest price of $22.84 as on March 11, 2026 at 1:29 am IST, you will get 0.4378 shares of Ultragenyx Pharmaceutical Inc.. Learn more about fractional shares .

What are the returns that Ultragenyx Pharmaceutical Inc. has given to Indian investors in the last 5 years?

Ultragenyx Pharmaceutical Inc. stock has given -81.15% share price returns and 26.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?